Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women.
about
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsHIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesPerformance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediatorsRelease of tenofovir from carrageenan-based vaginal suppositories.Studying the effects of reproductive hormones and bacterial vaginosis on the glycome of lavage samples from the cervicovaginal cavity.Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage.Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal ringsArginine- and Polyamine-Induced Lactic Acid Resistance in Neisseria gonorrhoeae.Using modeling to help understand vaginal microbicide functionality and create better products.The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal FluidSafety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring.Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide.Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time.Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samplesEffect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya.Engineering and characterization of simplified vaginal and seminal fluid simulants.Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine ModelChanges in the soluble mucosal immune environment during genital herpes outbreaks.Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates.Lower genital tract cytokine profiles in South African women living with HIV: influence of mucosal samplingGriffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivoPhysiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
P2860
Q28485356-132AC7C2-39E7-43D8-B203-F98C7CA55B10Q33939974-C84E5043-84E8-43A4-A431-0C47FE7B80E2Q33999185-A126060F-405D-48D8-B42C-C10CC0A8597AQ34309823-0126C48A-4598-4791-BFB9-9ACAF2A5D8AAQ35629244-2A07DE58-8398-45B5-9875-720E3A92F5D6Q35683986-5B46F0F7-6862-4E74-A9B0-39A6EFEB60E1Q35806225-E1326C95-FA5E-4347-8F83-12A9A3297FBCQ35903474-D971B45F-B00F-485B-A89F-B97BCD4AA718Q35913838-39B80DEF-1101-4294-BEDB-2544D1349708Q36082673-C0033583-C94F-43BE-8B48-E3FB55F39350Q36088773-D565E54C-E098-48AF-9D33-39AD57059AA3Q36617533-1F4FF1EB-3CC0-47C8-A7E6-B881E9CA3246Q36702615-CFE007BC-237F-44A8-A4F6-B4CDBA44468BQ36730523-5D576B93-2AF4-4B90-85E1-C6A67DACBEE8Q36889265-A0D68BE6-CA71-4A7E-B4B1-16675946C39AQ36890847-559163EF-665C-4A87-8D84-3AF39AEA1E57Q36933498-E21C5BD6-99B2-41B5-9527-3AD0AD8B7D51Q36937188-0FC08326-757A-4726-9123-7B7F04A09963Q37023114-83E21844-DF89-47F1-8ABA-B3A016CD2E48Q40239519-E7E7EAEA-66CA-4D22-B46B-E4B02FB2D20AQ47678273-0DB4B738-1E2B-4F47-9185-759555C2A9E5Q56970073-9ABAEC8E-1A59-4923-8EF4-B9203B821E7CQ58700581-BE8C98F1-00C6-423F-9992-1841D65D63A2Q58736449-14445B9B-FE8B-4B6D-8D2C-9E2745B66736
P2860
Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@ast
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@en
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@nl
type
label
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@ast
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@en
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@nl
prefLabel
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@ast
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@en
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@nl
P2093
P2860
P356
P1476
Estimating volume of cervicova ...... tal HIV-1 RNA levels in women.
@en
P2093
Caroline Mitchell
Jane Hitti
Kathleen Paul
Kathy Agnew
Reggie Gaussman
Robert W Coombs
P2860
P304
P356
10.1128/JCM.00991-10
P407
P577
2010-11-24T00:00:00Z